Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BMLBMLKF 68 Cash-to-Debt is 11.40 as of Jun. 2026, which is 22% below its 10-year median of 14.68. GuruFocus rates BMLKF with a GF Score™ of 68/100 and a GF Value™ of $27.26. The stock has 2 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, BML ranks better than 82.69% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BML's cash to debt ratio for the quarter that ended in Jun. 2026 was 11.40.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BMLcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for BML's Cash-to-Debt or its related term are showing as below:
BMLKF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 11.08 Med: 14.68 Max: 27.67
Current: 11.08
During the past 13 years, BML's highest Cash to Debt Ratio was 27.67. The lowest was 11.08. And the median was 14.68.
BMLKF's Cash-to-Debt is ranked better than 82.69% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs BMLKF: 11.08
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
BML Cash-to-Debt Related Terms
BML Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for BML's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, BML's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where BML's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BML (BMLKF) has a Cash-to-Debt of 11.40 as of Jun. 2026. This is 22% below median its historical median of 14.68. Over the past decade, BML's Cash-to-Debt has ranged from 11.08 to 27.67. According to the industry distribution chart, BML ranks #36 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 17.3%.
Is BML's Cash-to-Debt too high?
BML's current Cash-to-Debt of 11.40 is 22% below median its 10-year median of 14.68. Over the past 10 years, this metric has ranged from a low of 11.08 to a high of 27.67. The Medical Diagnostics & Research industry median Cash-to-Debt is 0.98. BML's value of 11.40 is 1063.3% above this industry median. Based on the distribution chart, BML ranks #36 out of 208 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BML has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does BML's Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #36 out of 208 companies for Cash-to-Debt. This places BML in the top 17% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. BML's value of 11.40 is 1063.3% above this benchmark. Historically, BML's own Cash-to-Debt has ranged from 11.08 to 27.67 over the past decade. While the company's 10-year median is 14.68 vs. the industry median of 0.98, BML has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BML's current Cash-to-Debt of 11.40 is 1063.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BML's current Cash-to-Debt is 11.40, which is 22% below median its own 10-year median of 14.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current Cash-to-Debt of 11.40. The stock's GF Value™ is $27.26, compared to a current price of $25.21 — trading 7.5% below its estimated fair value. The current Cash-to-Debt is 11.40, which is 22% below median its 10-year median of 14.68 and 1063.3% above the Medical Diagnostics & Research industry median of 0.98. BML's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For BML (BMLKF), the current Cash-to-Debt is 11.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 7.5% below its estimated GF Value™ of $27.26.
Key valuation signals for BMLKF:
Cash-to-Debt: 11.40 (22% below median its 10-year median of 14.68)
GF Value™: $27.26 vs. price of $25.21 (7.5% below fair value)
Industry Position: 1063.3% above the Medical Diagnostics & Research median (#36 of 208)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
68GF Score
Get the complete analysis for BMLKF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
